Increased BARDA Award and Option Exercise Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract...